USD 186.97
(-1.96%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 24.84 Million USD | 180.05% |
2022 | 8.87 Million USD | -73.74% |
2021 | 33.78 Million USD | 10.29% |
2020 | 30.63 Million USD | 24.92% |
2019 | 24.52 Million USD | -1.62% |
2018 | 24.92 Million USD | 51.43% |
2017 | 16.46 Million USD | 4.9% |
2016 | 15.69 Million USD | 0.0% |
2015 | - USD | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q1 | 24.5 Million USD | -1.39% |
2024 Q2 | 24.51 Million USD | 0.05% |
2024 Q3 | 25.21 Million USD | 3.32% |
2023 FY | 24.84 Million USD | 180.05% |
2023 Q3 | 25.17 Million USD | 7.72% |
2023 Q2 | 23.36 Million USD | 225.25% |
2023 Q1 | 7.18 Million USD | -19.01% |
2023 Q4 | 24.84 Million USD | -1.3% |
2022 Q1 | 34.27 Million USD | 1.45% |
2022 Q4 | 8.87 Million USD | -2.84% |
2022 FY | 8.87 Million USD | -73.74% |
2022 Q3 | 9.13 Million USD | -70.87% |
2022 Q2 | 31.34 Million USD | -8.56% |
2021 Q1 | 30.76 Million USD | 0.43% |
2021 FY | 33.78 Million USD | 10.29% |
2021 Q4 | 33.78 Million USD | 8.87% |
2021 Q3 | 31.03 Million USD | 0.44% |
2021 Q2 | 30.89 Million USD | 0.43% |
2020 Q4 | 30.63 Million USD | 23.65% |
2020 Q1 | 25.16 Million USD | 2.61% |
2020 FY | 30.63 Million USD | 24.92% |
2020 Q2 | 24.97 Million USD | -0.76% |
2020 Q3 | 24.77 Million USD | -0.78% |
2019 Q1 | 24.36 Million USD | -2.25% |
2019 FY | 24.52 Million USD | -1.62% |
2019 Q4 | 24.52 Million USD | 0.22% |
2019 Q3 | 24.46 Million USD | 0.22% |
2019 Q2 | 24.41 Million USD | 0.21% |
2018 Q3 | 24.81 Million USD | 0.48% |
2018 FY | 24.92 Million USD | 51.43% |
2018 Q2 | 24.69 Million USD | 0.51% |
2018 Q1 | 24.57 Million USD | 49.28% |
2018 Q4 | 24.92 Million USD | 0.45% |
2017 Q1 | - USD | 0.0% |
2017 Q4 | 16.46 Million USD | 0.0% |
2017 FY | 16.46 Million USD | 4.9% |
2016 FY | 15.69 Million USD | 0.0% |
2015 FY | - USD | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
Abbott Laboratories | 15.87 Billion USD | 99.843% |
Allurion Technologies Inc. | 41.85 Million USD | 40.641% |
Artivion, Inc. | 359.34 Million USD | 93.086% |
Avanos Medical, Inc. | 209.1 Million USD | 88.118% |
Butterfly Network, Inc. | 25.02 Million USD | 0.723% |
Butterfly Network, Inc. | 25.02 Million USD | 0.723% |
Bio-Rad Laboratories, Inc. | 1.4 Billion USD | 98.233% |
Boston Scientific Corporation | 9.49 Billion USD | 99.738% |
Perspective Therapeutics, Inc. | - USD | -Infinity% |
CONMED Corporation | 991.25 Million USD | 97.493% |
Edwards Lifesciences Corporation | 694.9 Million USD | 96.425% |
Paragon 28, Inc. | 112.03 Million USD | 77.822% |
Glaukos Corporation | 383.73 Million USD | 93.525% |
Globus Medical, Inc. | 520.4 Million USD | 95.226% |
Integer Holdings Corporation | 1.04 Billion USD | 97.613% |
Medtronic plc | 26.04 Billion USD | 99.905% |
Nevro Corp. | 221.82 Million USD | 88.799% |
Owlet, Inc. | 15.21 Million USD | -63.289% |
Penumbra, Inc. | 234.34 Million USD | 89.398% |
Vicarious Surgical Inc. | 14.83 Million USD | -67.516% |
Smith & Nephew plc | 3.08 Billion USD | 99.194% |
Sonendo, Inc. | 40.35 Million USD | 38.425% |
STERIS plc | 3.38 Billion USD | 99.266% |
Stryker Corporation | 12.99 Billion USD | 99.809% |
Vapotherm, Inc. | 112.39 Million USD | 77.893% |
Zimmer Biomet Holdings, Inc. | 5.99 Billion USD | 99.586% |